drugset

drugset / Trial / NCT05211284

Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US

NCT05211284 ↗

Phase 2 Terminated 4 enrolled Zydus Therapeutics Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Saroglitazar Magnesium 4 mg for NAFLD in People Living with HIV in the US

Timeline

Start: 2022-12-08
Primary completion: 2023-10-02
Completion: 2023-10-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Saroglitazar	Small molecule	4 mg	Oral

Indications